Ibiglustat (Synonyms: Venglustat; SAR402671; GZ402671)

Name: Ibiglustat
Brand: MedChemExpress
SKU: HY-16743
Rating: 5.0 (3 reviews)

Cat. No.: HY-16743 Purity: 99.81%: Data Sheet
SDS

COA
Handling Instructions Technical Support

Solubility

In Vivo Dissolution Calculator

Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.

For research use only. We do not sell to patients.

Ibiglustat Chemical Structure

CAS No. : 1401090-53-6

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 162	In-stock	Estimated Time of Arrival: April 4
Solution
10 mM * 1 mL in DMSO	USD 171	In-stock	Estimated Time of Arrival: April 4
Solid
2 mg	USD 100	In-stock	Estimated Time of Arrival: April 4
5 mg	USD 200	In-stock	Estimated Time of Arrival: April 4
10 mg	USD 360	In-stock	Estimated Time of Arrival: April 4
25 mg	USD 640	In-stock	Estimated Time of Arrival: April 4
50 mg	USD 960	In-stock	Estimated Time of Arrival: April 4
100 mg	USD 1440	In-stock	Estimated Time of Arrival: April 4
200 mg		Get quote
500 mg		Get quote

Get it by April 4 for select sizes. Order within 23 hrs 37 mins.

or Bulk Inquiry

* Please select Quantity before adding items.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Ibiglustat:

3 Publications Citing Use of MCE Ibiglustat

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Glucosylceramide synthase^[1].

In Vitro

Ibiglustat (SAR402671) (1 μM, 15 days; Fabry disease (FD) cells) is close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes^[4]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03687554	Genzyme, a Sanofi Company\|Sanofi	Healthy Volunteers\|Polycystic Kidney, Autosomal Dominant	October 5, 2018	Phase 1
NCT02906020	Genzyme, a Sanofi Company\|Sanofi	Parkinson´s Disease	December 15, 2016	Phase 2
NCT03523728	Genzyme, a Sanofi Company\|Sanofi	Polycystic Kidney, Autosomal Dominant	October 4, 2018	Phase 2\|Phase 3
NCT05280548	Genzyme, a Sanofi Company\|Sanofi	Fabry Disease	May 3, 2022	Phase 3
NCT02843035	Genzyme, a Sanofi Company\|Sanofi	Gaucher Disease Type 1\|Gaucher Disease Type 3	January 4, 2017	Phase 2
NCT04705051	Sanofi	Congenital Cystic Kidney Disease	February 9, 2021	Phase 3
NCT04221451	Genzyme, a Sanofi Company\|Sanofi	Tay-Sachs Disease Sandhoff Disease	June 29, 2020	Phase 3
NCT05718258	Sanofi	Hepatic Function Abnormal	January 18, 2023	Phase 1
NCT05222906	Genzyme, a Sanofi Company\|Sanofi	Gaucher´s Disease Type III	April 18, 2022	Phase 3
NCT05206773	Genzyme, a Sanofi Company\|Sanofi	Fabry Disease	March 11, 2022	Phase 3
NCT05238714	Genzyme, a Sanofi Company\|Sanofi	Disorders of Sphingolipid Metabolism (Healthy Volunteers)	May 26, 2020	Phase 1

Molecular Weight

389.49

Formula

C₂₀H₂₄FN₃O₂S

CAS No.

1401090-53-6

Appearance

Solid

Color

White to off-white

SMILES

O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (128.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5675 mL	12.8373 mL	25.6746 mL
5 mM	0.5135 mL	2.5675 mL	5.1349 mL
10 mM	0.2567 mL	1.2837 mL	2.5675 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, PEG300/PEG400, Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Purity & Documentation

Purity: 99.81%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (247 KB)

Handling Instructions (2659 KB)

References

[1]. Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11(1):20945. Published 2021 Oct 22. [Content Brief]

[2]. Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10(1):86-98. [Content Brief]

[3]. Stojkovska I, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. Cell Tissue Res. 2018;373(1):51-60. doi:10.1007/s00441-017-2704-y [Content Brief]

[4]. Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5675 mL	12.8373 mL	25.6746 mL	64.1865 mL
	5 mM	0.5135 mL	2.5675 mL	5.1349 mL	12.8373 mL
	10 mM	0.2567 mL	1.2837 mL	2.5675 mL	6.4187 mL
	15 mM	0.1712 mL	0.8558 mL	1.7116 mL	4.2791 mL
	20 mM	0.1284 mL	0.6419 mL	1.2837 mL	3.2093 mL
	25 mM	0.1027 mL	0.5135 mL	1.0270 mL	2.5675 mL
	30 mM	0.0856 mL	0.4279 mL	0.8558 mL	2.1396 mL
	40 mM	0.0642 mL	0.3209 mL	0.6419 mL	1.6047 mL
	50 mM	0.0513 mL	0.2567 mL	0.5135 mL	1.2837 mL
	60 mM	0.0428 mL	0.2140 mL	0.4279 mL	1.0698 mL
	80 mM	0.0321 mL	0.1605 mL	0.3209 mL	0.8023 mL
	100 mM	0.0257 mL	0.1284 mL	0.2567 mL	0.6419 mL

Ibiglustat Related Classifications

Metabolic Disease

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ibiglustat (Synonyms: Venglustat; SAR402671; GZ402671)

Customer Review

Other Forms of Ibiglustat:

Ibiglustat Related Antibodies

3 Publications Citing Use of MCE Ibiglustat

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

Biological Activity

Purity & Documentation

References

Customer Review

Ibiglustat Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ibiglustat Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report